At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 16 Week Randomised, Open Labelled, 3 Armed, Parallel Group, Treat-to-target Trial Comparing Once Daily Injection of SIAC 30 (B), SIAC 45 (B) and Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment
In Brief
A Phase 2 clinical trial evaluating insulin degludec/insulin aspart, insulin glargine, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 178 participants across 28 sites in 5 countries.
Detailed Summary
This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (SIAC, insulin degludec/insulin aspart) formulations with each other and with insulin glargine, all in combination with metformin in insulin naive subjects with type 2 diabetes.
Study Details
Timeline
Interventions
Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily
Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily
Treat-to-target dose titration scheme, injection s.c., once daily
Tablets, 1500-2000 mg/day